Please login to the form below

RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.

Roche's Actemra/RoActemra receives new European approval

GCA is a chronic and potentially life-threatening autoimmune condition and Actemra/RoActemra’s approval was based on data from the phase III GiACTA study. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to
Ocrevus off to a flying start as Roche raises 2017 forecasts

Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
Manufacturing issues scupper Sanofi's sarilumab launch plans

Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
Roche snags pair of FDA breakthrough designations

Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Achieving remission

Campaign:RoACTEMRA / ACTEMRA: beyond the boundaries of existing treatments. Timescale:2008 to 2009. ... Online monitoring tools tracked RoACTEMRA / ACTEMRA noise, identifed top influencers and tonality of digital conversations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market
Brand leaders in RA will lose market share, predict rheumatologists

leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...